Clinical Study: Type 1 Diabetes (T1D)

Status: Enrolling

Email: diabetes@benaroyaresearch.org

Phone: (800) 888-4187

Study Summary

The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.

Ages 15-40 will be enrolled first, followed by 5 to 40-year-olds later in the study.

Eligibility Criteria

You/your child may qualify to participate in the SAFEGUARD clinical study if the following criteria are met:

• Aged between 5 to 40 years, inclusively
• Newly diagnosed with T1D (enrolled in the study within 100 days of diagnosis)

What will study participants be asked to do?

If you/your child qualify to participate:

• You/they will be assigned to either Part A or Part B treatment, depending on when you/they are enrolled into the study.
• For both Part A and Part B, all groups will receive 2 treatment courses, 6 months apart. Each treatment course will be given via intravenous infusion (i.e. via a small tube placed into a vein) over 2 days.
• There will be 7 scheduled follow-up visits and 3 phone calls to monitor the safety and efficacy of the treatment
• You/your child will NOT be charged for the study medicine or placebo, study visits, or tests and procedures needed for the study
• You/your child are free to leave the study at any time

For more information visit: https://clinicaltrials.gov/study/NCT07187531